文献速递结核与非结核分枝杆菌

耐多药结核治疗中以贝达喹啉替代二线注射剂可改善治疗结局:一项回顾性队列研究

Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该回顾性队列研究纳入南非西开普省162例接受贝达喹啉替代二线注射剂治疗的耐多药结核成人患者及168例未接受贝达喹啉的匹配对照,70.6%合并人类免疫缺陷病毒感染。贝达喹啉组12个月不良结局比例为23.9%(35/146),低于对照组的36.2%(51/141),相对风险为0.66(95%CI 0.46-0.95)。贝达喹啉组培养复阳患者1例(0.8%),少于对照组的12例(10.3%,P=0.001)。

要点

  • 贝达喹啉替代二线注射剂组12个月不良结局比例低于对照组(23.9% vs 36.2%,RR 0.66,95%CI 0.46-0.95)。
  • 贝达喹啉组培养复阳1例(0.8%),对照组12例(10.3%),P=0.001。
  • 贝达喹啉延迟启动与未能达到持续培养阴转独立相关(每延迟30天调整OR 1.5,95%CI 1.1-1.9)。

核心结论

  • 在耐多药结核治疗中以贝达喹啉替代二线注射剂,与继续使用二线注射剂的患者相比,12个月结局改善,支持在规划性环境中使用贝达喹啉治疗耐多药结核。

研究设计与样本

  • 回顾性队列研究,从南非西开普省电子结核登记库中识别接受贝达喹啉替代治疗的耐多药结核成人患者,并设未接受贝达喹啉的匹配对照组。
  • 贝达喹啉组162例,对照组168例;70.6%感染人类免疫缺陷病毒。

主要发现

  • 主要结局(治疗12个月时死亡、失访或未能达到持续培养阴转)在贝达喹啉组146例中发生35例(23.9%),对照组141例中发生51例(36.2%),相对风险0.66(95%CI 0.46-0.95)。
  • 培养复阳患者在贝达喹啉组为1例(0.8%),对照组为12例(10.3%),P=0.001。
  • 贝达喹啉延迟启动与未能达到持续培养阴转独立相关,每延迟30天的调整比值比为1.5(95%CI 1.1-1.9)。
  • 12个月死亡率两组相似,每组各死亡11例,P=0.97。

临床怎么用

  • 作者认为,在耐多药结核治疗中以贝达喹啉替代二线注射剂可改善12个月结局,支持在规划性环境中使用贝达喹啉治疗耐多药结核。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bedaquiline is used as a substitute for second-line injectable (SLI) intolerance in the treatment of multidrug-resistant (MDR) tuberculosis, but the efficacy and safety of this strategy is unknown. METHODS: In this retrospective cohort study adults receiving bedaquiline substitution for MDR tuberculosis therapy, plus a matched control group who did not receive bedaquiline, were identified from the electronic tuberculosis register in the Western Cape Province, South Africa. The primary outcome measure was the proportion of patients with death, loss to follow-up, or failure to achieve sustained culture conversion at 12 months of treatment. RESULTS: Data from 162 patients who received bedaquiline substitution and 168 controls were analyzed; 70.6% were infected with human immunodeficiency virus. Unfavorable outcomes occurred in 35 of 146 (23.9%) patients in the bedaquiline group versus 51 of 141 (36.2%) in the control group (relative risk, 0.66; 95% confidence interval, .46 -.95). The number of patients with culture reversion was lower in those receiving bedaquiline (1 patient; 0.8%) than in controls (12 patients; 10.3%; P = .001). Delayed initiation of bedaquiline was independently associated with failure to achieve sustained culture conversion (adjusted odds ratio for every 30-day delay, 1.5; 95% confidence interval, 1.1-1.9). Mortality rates were similar at 12 months (11 deaths in each group; P = .97). CONCLUSIONS: Substituting bedaquiline for SLIs in MDR tuberculosis treatment resulted in improved outcomes at 12 months compared with patients who continued taking SLIs, supporting the use of bedaquiline for MDR tuberculosis treatment in programmatic settings.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Fox T, Manning K, et al. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study. Clin Infect Dis. 2019. PMID: 30165431. doi:10.1093/cid/ciy727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。